Concert Pharmaceuticals Inc. (CNCE)

10.76
NASDAQ : Health Technology
Prev Close 11.02
Day Low/High 10.69 / 11.16
52 Wk Low/High 9.21 / 20.21
Avg Volume 320.60K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 262.23M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Concert Pharmaceuticals Presents CTP-543 Phase 1 Results At American Academy Of Dermatology Annual Meeting

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the results from the Company's Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers were presented in a poster...

Concert Pharmaceuticals To Report Full Year 2016 Results On March 6, 2017, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2016, on Monday, March 6, 2017, before the U.

Concert Pharmaceuticals Receives FDA Orphan Drug Designation For CTP-656 For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals Receives FDA Orphan Drug Designation For CTP-656 For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.

Concert Pharmaceuticals Provides Further Details On CTP-656 Development In U.S. And Europe

Concert Pharmaceuticals Provides Further Details On CTP-656 Development In U.S. And Europe

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today provided further details on the development plan in the U.

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a U.

Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results

Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers has been completed.

Concert Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Third Quarter 2016 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2016.

Concert Pharmaceuticals To Report Third Quarter 2016 Financial Results On November 8, 2016, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Report Third Quarter 2016 Financial Results On November 8, 2016, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2016 financial results on Tuesday, November 8, 2016, before the U.

Concert Pharmaceuticals Presents Poster At 2016 North American Cystic Fibrosis Conference

Concert Pharmaceuticals Presents Poster At 2016 North American Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented a poster describing Phase 1 food effect and multiple ascending dose results of CTP-656 at the North American Cystic Fibrosis Conference being held in...

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Announces Upcoming Poster Presentation At North American Cystic Fibrosis Conference

Concert Pharmaceuticals Announces Upcoming Poster Presentation At North American Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Company will present a poster at the 30th Annual North American Cystic Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida.

Concert Pharmaceuticals Expands Management Team

Concert Pharmaceuticals Expands Management Team

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the expansion of its senior management team with the appointment of executives in regulatory affairs and commercial strategy to serve in leadership roles...

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2016 Healthcare...

Concert Pharmaceuticals is Now Oversold (CNCE)

Concert Pharmaceuticals is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2016.

Concert Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016

Concert Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2016 financial results on Tuesday, August 9, 2016, before the U.

Commit To Buy Concert Pharmaceuticals At $10, Earn 24.9% Annualized Using Options

Commit To Buy Concert Pharmaceuticals At $10, Earn 24.9% Annualized Using Options

Investors considering a purchase of Concert Pharmaceuticals Inc shares, but cautious about paying the going market price of $11.90/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $10 strike, which has a bid at the time of this writing of $1.20.

Concert Pharmaceuticals Announces Webcast At Cantor Fitzgerald Healthcare Conference

Concert Pharmaceuticals Announces Webcast At Cantor Fitzgerald Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 13, 2016, at 2:30 p.

CNCE: Insiders vs. Shorts

CNCE: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Concert Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 7.86 "days to cover" versus the median component at 6.29. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Concert Pharmaceuticals is Now Oversold (CNCE)

Concert Pharmaceuticals is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Presents CTP-656 Phase 1 Results At European Cystic Fibrosis Conference

Concert Pharmaceuticals Presents CTP-656 Phase 1 Results At European Cystic Fibrosis Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ascending dose trial of CTP-656, a next generation CFTR potentiator being developed for the treatment of cystic fibrosis.

Concert Pharmaceuticals Initiates Phase 1 Trial Of CTP-543 As A New Treatment For Alopecia Areata

Concert Pharmaceuticals Initiates Phase 1 Trial Of CTP-543 As A New Treatment For Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for...

Concert Pharmaceuticals To Present At Several Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Several Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The UBS 2016 Global Healthcare Conference on May...

Concert Pharmaceuticals Becomes Oversold (CNCE)

Concert Pharmaceuticals Becomes Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports First Quarter 2016 Financial Results

Concert Pharmaceuticals Reports First Quarter 2016 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016.

Concert Pharmaceuticals Unveils CTP-543 For Treatment Of Alopecia Areata

Concert Pharmaceuticals Unveils CTP-543 For Treatment Of Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced its next product candidate, CTP-543, for the treatment of alopecia areata.

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 26.7% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 26.7% Annualized Using Options

Investors considering a purchase of Concert Pharmaceuticals Inc stock, but tentative about paying the going market price of $13.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $12.50 strike, which has a bid at the time of this writing of $1.60.

Concert Pharmaceuticals Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline data from a Phase 1 multiple ascending dose clinical trial of CTP-656.

Concert Pharmaceuticals To Report First Quarter 2016 Financial Results On May 5, 2016

Concert Pharmaceuticals To Report First Quarter 2016 Financial Results On May 5, 2016

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2016 financial results on Thursday, May 5, 2016, before the U.

7 Stocks Rising on Big Volume -- Here's How to Trade Them Now

7 Stocks Rising on Big Volume -- Here's How to Trade Them Now

Here's a technical look at how to trade seven stocks that were spiking on unusual volume recently.

TheStreet Quant Rating: D (Sell)